Observational studyNeonatology2026
Antimicrobial Use Monitoring in Neonatal Population Using a Defined Daily Doses Method.
Observational study in Neonatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedErratum.2026
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to assess the feasibility of using specific defined daily doses for neonates (DDDn) as a standardized metric for monitoring antimicrobial consumption in neonatal populations, thereby enhancing antimicrobial stewardship programs (ASPs). To this end, DDDn values have been established for those antimicrobials that had not previously been defined.
methodsThis observational study was conducted in the Neonatology Unit of a tertiary-care teaching hospital. Data on antimicrobial use were prospectively collected from January 2016 to December 2023. Both the DDDn values validated in a previous study and the new DDDn values obtained in the present work were used. Antimicrobial consumption was measured quarterly and expressed as DDDn per 1,000 occupied bed days (OBDs). Additionally, a conversion factor was defined to transform DDD into DDDn.
resultsOut of 1,326 prescriptions, 310 met the inclusion criteria. The study successfully validated DDDn for 10 antimicrobials, including piperacillin-tazobactam, cefepime, and amoxicillin-clavulanic acid. However, DDDn for certain antimicrobials could not be established due to insufficient prescribing data. The mean global antimicrobial consumption was 5.271 ± 1.435 DDDn per 1,000 OBDs per year. The most commonly used antimicrobials were cefotaxime, amoxicillin-clavulanic acid, and ampicillin. The conversion factor was established for five oral antimicrobials and 17 intravenous ones.
conclusionDDDn proved to be a feasible tool for monitoring antimicrobial consumption in neonatal populations, offering a standardized metric that could improve ASPs and optimize antibiotic usage. More research is needed to validate DDDn across different antimicrobials and clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.